Pad­cev, Keytru­da’s new sur­vival da­ta; Ser­ax­is rais­es $10M for di­a­betes cell ther­a­py

Last year
News Briefing

Six years af­ter with­draw­ing IPO, Abpro takes SPAC route to Nas­daq — with plans to take HER2 bis­pe­cif­ic to clin­ic

Last year
Deals

In­di­a's Glen­mark Phar­ma­ceu­ti­cals di­vests 75% stake in its API man­u­fac­tur­ing sub­sidiary

Last year
R&D
Manufacturing

As­traZeneca, Dai­ichi Sankyo eye first ap­proval for TROP2 drug af­ter PhI­II breast can­cer suc­cess

Last year
R&D

Mark Vel­le­ca takes over at Black Di­a­mond; Verve Ther­a­peu­tics sep­a­rates CMO, CSO posts

Last year
Peer Review

Roche scru­ti­nized by UK watch­dog over 'mis­lead­ing' Ro­z­lytrek pro­mo­tion­al web­site

Last year
Pharma
Marketing

GE Health­Care hits the road in a health tech bus to bring its lat­est so­lu­tions to hos­pi­tal doorsteps

Last year
Pharma
Marketing

An of­fer you can't refuse: De­moc­rats and Re­pub­li­cans trade barbs over in­com­ing drug price ne­go­ti­a­tions

Last year
Law

Q&A: No­vo Nordisk Foun­da­tion’s Celler­a­tor CEO Thomas Carlsen digs in­to $135.4M Dan­ish cell ther­a­py fa­cil­i­ty

Last year
Cell/Gene Tx
Manufacturing

GSK's Vi­iV Health­care takes Shut­ter­stock-part­nered cam­paign in new di­rec­tion

Last year
Pharma
Marketing

In new draft guid­ance for man­u­fac­tur­ing in­spec­tions, FDA draws in­spi­ra­tion from pan­dem­ic meth­ods

Last year
FDA+
Manufacturing

Tra­vere Ther­a­peu­tics just miss­es on con­fir­ma­to­ry study for kid­ney dis­ease drug, stock plum­mets

Last year
R&D

Af­ter Ver­sa­nis suc­cess, Adi­tum launch­es Celex­or Bio with au­toim­mune drug from Ace­lyrin part­ner In­ma­gene

Last year
Financing
Startups

He­palys to de­vel­op In­ven­ti­va’s NASH treat­ment; Ever­est li­cens­es Kezar’s au­toim­mune drug

Last year
News Briefing

Sam­sung Bi­o­log­ics locks $242M BMS deal; Fu­ture Fields launch­es CD­MO arm; SK pharmte­co takes con­trol of CBM

Last year
Manufacturing

Au­rinia ap­points founder to board in hand­shake with MKT Cap­i­tal

Last year
People

The End­points 11: The biotech star­tups mak­ing the biggest bets with the most ex­cit­ing sci­ence in 2023

Last year
Startups
Special

Ex­clu­sive: As­traZeneca signs off on a ‘car­bon neg­a­tive’ new biotech build­ing for one of its lat­est buy­outs

Last year
Bioregnum
Pharma

A new George Church start­up rais­es $16M. The first-time founders have a ‘crazy vi­sion’ to bring ML to cell ...

Last year
Financing
Startups

Up­dat­ed: So­ci­etal CD­MO lays off 26 em­ploy­ees, re­works hir­ing plans af­ter strat­e­gy re­view

Last year
People
Manufacturing

Look­ing for an edge in a com­pet­i­tive mar­ket, Ox­ford Nanopore moves in­to mR­NA vac­cine test­ing

Last year
Outsourcing
Manufacturing

No­vo Nordisk’s US semaglu­tide man­u­fac­tur­ing site un­der the spot­light again as 2022 mon­i­tor­ing is­sue sur­faces

Last year
Pharma
Manufacturing

Physi­cians see ‘new era for weight loss med­ica­tions’ with the ar­rival of No­vo, Lil­ly GLP-1 meds, sur­vey says

Last year
Pharma
Marketing

Ac­tor Er­ic Ston­estreet talks about his re­al 'mod­ern fam­i­ly' in aware­ness cam­paign for eye dis­ease

Last year
Pharma
Marketing
First page Previous page 276277278279280281282 Next page Last page
A service from the Financial Times